News

Balt receives IDE approval from the FDA to begin the STEM Trial

May 14, 2020

Balt announced today it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma.

Discover the Press Release

Other News

Previous Next
slide 11 to 15 of 6
News
Sep 18, 2024

Official visit to our site in Montmorency, France

Read More
Official visit to our site in Montmorency, France
News
Feb 06, 2025

Balt featured at the “Annales des Mines”

Read More
Balt featured at the “Annales des Mines”
News
Feb 05, 2025

Balt is hiring!

Read More
Balt
News
Dec 20, 2024

Balt secures €355 million to refinance its debt and accelerate its growth

Read More
Balt
News
Nov 22, 2024

STEM trial results in the New England Journal of Medicine (NEJM)

Read More
STEM trial results in the New England Journal of Medicine (NEJM)
Previous Next
Close
Balt Lab

Contact Us

Need more information? We are here to help.

Certain products may not be available in your region. Contact us for more information.
I UNDERSTAND

BALT uses cookies on this website to :
— To assist you during browsing;
— To enable certain website features;
— To provide analysis;
— To save your preferences;
— To select the right content framework to serve you based on your geolocation.

By continuing to use this website, you consent to the use of cookies.

For any questions regarding the use of cookies, please refer to BALT’s cookie policy.


I agree I disagree
EN
FR EN